A hormone best known for suppressing appetite just revealed a second, entirely separate job. Researchers at McMaster University found that when GDF15 is active in the body, it doesn’t just make people eat less. It sends a message to the brain, which then relays instructions back down to the liver, quieting the kind of chronic inflammation that turns fatty liver disease into something far more dangerous. The appetite connection was already well-documented. This second pathway was not.
Losing weight remains one of the most effective ways to protect a liver burdened by excess fat, and newer GLP-1 medications have made that easier for many patients. But weight loss doesn’t always solve the full problem.
Liver inflammation often persists even after significant weight loss. That persistent inflammation is the part of the disease that can quietly progress toward catastrophic outcomes, even in people whose weight and liver fat have genuinely improved. August 2026 research from McMaster University published in Cell Metabolism suggests there may now be a biological pathway that addresses exactly that gap, and the key player in that pathway is a hormone called GDF15.
What MASH Actually Does to the Liver
MASH stands for metabolic dysfunction-associated steatohepatitis, a term that describes a liver that isn’t just fatty but actively inflamed and being damaged from within. It is a severe form of fatty liver disease that can progress to cirrhosis, liver cancer, and liver failure if inflammation continues unchecked.
Growth differentiation factor 15 (GDF15) suppresses liver inflammation and fibrosis in MASH independently of reduced food intake, body weight, or steatosis (fat accumulation in the liver). When calorie intake was held constant in the mouse models used for the study, the liver still improved – meaning the liver-protective effect didn’t vanish when weight loss was taken off the table.
The mechanism behind this runs through two organs that most people wouldn’t think of as partners in liver protection. GDF15 activates signaling from the brain through the nervous system, leading to the release of glucocorticoids, a class of steroid hormones that play a role in metabolism, immune function, and the body’s response to stress. Glucocorticoids are produced naturally by the adrenal glands and are closely related to the corticosteroid drugs that doctors prescribe to reduce inflammation in conditions like rheumatoid arthritis and severe asthma. In this case, the body generates them in response to a signal that started in the brain.
How the GDF15 Fatty Liver Pathway Works
Gregory Steinberg, professor in McMaster University’s Department of Medicine and Canada Research Chair in Metabolism and Obesity, stated in the McMaster press release: “We discovered that GDF15 activates a natural brain-to-liver signaling pathway that helps suppress liver inflammation and reduce fibrosis.”
The Cell Metabolism study was led by Dongdong Wang, first and corresponding author and assistant professor in McMaster’s Department of Medicine. The team used mouse models built to closely mimic advanced human MASH, combining genetic, pharmacological, genomic, and spatial transcriptomics approaches to investigate the role of GDF15 in advanced liver disease. Spatial transcriptomics is a technique that maps gene activity across different physical regions of tissue, allowing researchers to see which cells are doing what and where.
What they found was a cascade. GDF15 activates signaling from the brain through the nervous system, leading to glucocorticoid release by the adrenal glands. The glucocorticoids travel to the liver and begin shifting immune cells away from a highly activated, inflammation-promoting state toward a calmer profile.
Scarring, or fibrosis, is what determines long-term prognosis in MASH. The research identifies a biological pathway that helps regulate liver inflammation, and future treatments may be able to complement existing weight-loss therapies rather than replace them.
Fatty Liver’s Silent Progression
GDF15 had attracted attention primarily because it can suppress appetite and contribute to weight loss, and many of its health effects were thought to come mainly from people or animals eating less and becoming leaner. That framing shaped how researchers and pharmaceutical companies thought about its potential. If GDF15 just made people eat less, then it was another entry in the growing class of appetite-suppressing metabolic drugs – useful and interesting, but not breaking new conceptual ground.
Fatty liver disease, known medically as hepatic steatosis, is a condition in which excess fat accumulates in the liver. It has become increasingly common alongside obesity and type 2 diabetes. Unlike simple fatty liver, MASH pairs fat accumulation with active inflammation and liver cell damage. That inflammation is the engine of progression.
Liver fibrosis advances in stages. In early stages, the liver can still function relatively well. As fibrosis advances, cirrhosis becomes a real risk, and from cirrhosis the road leads toward liver cancer and liver failure. Symptoms are often absent until the disease is well along, which means people can have significant liver damage without knowing it – and losing weight alone may not stop the inflammatory process driving that damage.
You can read more about the warning signs that the liver is under stress at this overview on liver damage symptoms.
GDF15’s Second Major Discovery
This is the second major discovery from the same McMaster team involving GDF15. In 2023, Wang and Steinberg published findings in Nature showing that GDF15 does more than cut appetite during weight loss. In addition to suppressing appetite, GDF15 counteracts compensatory reductions in energy expenditure – meaning the body’s typical response of slowing calorie burn to compensate for dieting is blunted, leading to greater actual weight loss than calorie restriction alone would produce.
The 2026 finding is entirely separate from that mechanism. Where the 2023 study was about energy metabolism and muscle activity, the new work is about immune regulation and liver inflammation – two different pathways driven by one hormone.
Novo Nordisk provided research support and supplied the GDF15 hormone used in the study, which places the research within a broader pharmaceutical context. Novo Nordisk produces several GLP-1 receptor agonist medications, including semaglutide (sold under brand names including Ozempic and Wegovy). The GDF15 pathway is distinct from the GLP-1 mechanism, and the researchers note the possibility that combining both approaches could address different aspects of the same disease simultaneously.
What the Findings Could Mean for Treatment
GDF15 can help protect the liver from inflammation and scarring even when its effects on body weight are removed from the picture. That opens a new treatment concept: instead of targeting weight loss alone and hoping inflammation follows, future therapies might directly target the brain-to-liver signaling axis.
Glucocorticoids are powerful hormones with effects throughout the body. High doses of synthetic glucocorticoids are associated with side effects including blood sugar elevation, immune suppression, and bone density loss. Any treatment designed to deliberately raise natural glucocorticoid levels would need to be carefully calibrated to act locally on the liver’s immune cells without disrupting other systems. That work hasn’t been done yet.
More research is needed to confirm these findings in humans. What holds true in a mouse model doesn’t automatically translate to human patients with MASH, who are older, taking multiple medications, and living with overlapping metabolic conditions. The study’s authors note that larger cohorts with biopsy-confirmed MASH are needed before the relevance of this pathway in humans can be fully defined.
Read More: Popular Fiber Supplement May Not Be Suitable for Fatty Liver Disease
What to Do Now
If you or someone you know has been told they have fatty liver disease, the most practical takeaway from this research is that weight loss, while genuinely helpful, may not be doing all the work people assume it is. Inflammation can continue even after the scale changes, and it’s that inflammation – not just the fat – that scars the liver and drives long-term damage.
For anyone managing MASH or at risk through obesity or type 2 diabetes, ask your hepatologist or gastroenterologist not just about your weight trajectory but specifically about your liver inflammation markers. Standard blood work measures ALT and AST enzymes, and imaging can show whether fibrosis has already begun. The GDF15 research is still in animal stages and years away from a clinical therapy, but the pathway it reveals is biological and measurable. The body already has a system designed to protect the liver from exactly this kind of damage. The goal of future research is to find out how to reliably switch that system on.
Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.